PMID- 25056984
OWN - NLM
STAT- MEDLINE
DCOM- 20150710
LR  - 20220316
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
VI  - 81
IP  - 6
DP  - 2014 Dec
TI  - Role of (18) F-FDOPA PET/CT imaging in endocrinology.
PG  - 789-98
LID - 10.1111/cen.12566 [doi]
AB  - (18) F-FDOPA (6-[18F]-L-fluoro-L-3, 4-dihydroxyphenylalanine)-based PET/CT 
      imaging can be a useful tool for the detection of different neuroendocrine 
      tumours (NETs). (18) F-FDOPA is taken up into the cells via the neutral amino 
      acid transporter (LAT1/4F2hc). This transporter is also coupled to the mammalian 
      target of rapamycin (mTOR) signalling pathway. (18) F-FDOPA PET/CT may be 
      performed for confirmation of diagnosis of pheochromocytoma/paraganglioma, 
      staging at initial presentation, restaging and follow-up of patients. In 
      SDHx-related syndromes, (18) F-FDG PET/CT should be performed in addition to (18) 
      F-FDOPA PET/CT. (18) F-FDOPA PET/CT is also invaluable in the detection 
      staging/restaging of carcinoid tumours and has greater sensitivity as compared to 
      somatostatin receptor scintigraphy. (18) F-FDOPA PET/CT can also distinguish 
      between focal vs diffuse CHI. It is not as useful in adult hyperinsulinism due to 
      increased background uptake, but the problem may be overcome with the help of 
      premedication with carbidopa. It has limited use in pancreatic NETs. (18) F-FDOPA 
      PET/CT is a good modality for detection of persistent and residual medullary 
      thyroid cancer (MTC), but (18) F-FDG PET/CT may be needed in aggressive tumours. 
      In summary, F-DOPA PET/CT has widespread utility in the diagnosis of different 
      neuroendocrine tumours.
CI  - (c) 2014 John Wiley & Sons Ltd.
FAU - Santhanam, Prasanna
AU  - Santhanam P
AD  - Section of Endocrinology, Department of Internal Medicine, Joan C Edwards School 
      of Medicine, Marshall University, Huntington, WV, USA.
FAU - Taieb, David
AU  - Taieb D
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140901
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Dopamine Agents)
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - 2C598205QX (fluorodopa F 18)
RN  - 63-84-3 (Dihydroxyphenylalanine)
RN  - MNX7R8C5VO (Carbidopa)
RN  - Thyroid cancer, medullary
SB  - IM
MH  - Adrenal Gland Neoplasms/diagnostic imaging
MH  - Carbidopa
MH  - Carcinoid Tumor/diagnostic imaging
MH  - Carcinoma, Neuroendocrine
MH  - Dihydroxyphenylalanine/*analogs & derivatives
MH  - Dopamine Agents
MH  - *Fluorodeoxyglucose F18
MH  - Humans
MH  - Multimodal Imaging
MH  - Neuroendocrine Tumors/*diagnostic imaging
MH  - Paraganglioma/diagnostic imaging
MH  - Pheochromocytoma/diagnostic imaging
MH  - Positron-Emission Tomography
MH  - *Radiopharmaceuticals
MH  - Thyroid Neoplasms/diagnostic imaging
MH  - Tomography, X-Ray Computed
EDAT- 2014/07/25 06:00
MHDA- 2015/07/15 06:00
CRDT- 2014/07/25 06:00
PHST- 2014/05/01 00:00 [received]
PHST- 2014/06/03 00:00 [revised]
PHST- 2014/06/27 00:00 [revised]
PHST- 2014/07/21 00:00 [accepted]
PHST- 2014/07/25 06:00 [entrez]
PHST- 2014/07/25 06:00 [pubmed]
PHST- 2015/07/15 06:00 [medline]
AID - 10.1111/cen.12566 [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2014 Dec;81(6):789-98. doi: 10.1111/cen.12566. Epub 2014 
      Sep 1.